How much did PhenomeX achieve in EBIT for the current year?
In the current year, PhenomeX has achieved an EBIT of -53.08 M USD.
PhenomeX EBIT 2024
PhenomeX EBIT
-53.08 M USD
Ticker
CELL
ISIN
US0843101017
WKN
A2P9RR
In 2024, PhenomeX's EBIT was -53.08 M USD, a -41.81% increase from the -91.21 M USD EBIT recorded in the previous year.
The PhenomeX EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
PhenomeX Revenue, EBIT, Net Income US0843101017 · A2P9RR
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into PhenomeX, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PhenomeX from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PhenomeX’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of PhenomeX. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into PhenomeX’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing PhenomeX’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PhenomeX’s growth potential.
PhenomeX Revenue, EBIT and net profit per share
| Date | PhenomeX Revenue | PhenomeX EBIT | PhenomeX Net Income |
|---|---|---|---|
| 2026e | 182.58 M undefined | 0 undefined | -27.26 M undefined |
| 2025e | 135.93 M undefined | -44.17 M undefined | -28.07 M undefined |
| 2024e | 104.06 M undefined | -53.08 M undefined | -59.16 M undefined |
| 2023e | 78.03 M undefined | -91.21 M undefined | -116.1 M undefined |
| 2022 | 78.6 M undefined | -94.54 M undefined | -98.04 M undefined |
| 2021 | 85.39 M undefined | -70.79 M undefined | -71.72 M undefined |
| 2020 | 64.3 M undefined | -40.39 M undefined | -43.32 M undefined |
| 2019 | 56.69 M undefined | -16.54 M undefined | -21.5 M undefined |
| 2018 | 31.3 M undefined | -21.16 M undefined | -26.54 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 31.3 M USD | -21.16 M USD | -26.54 M USD |
| 2019 | 56.69 M USD | -16.54 M USD | -21.5 M USD |
| 2020 | 64.3 M USD | -40.39 M USD | -43.32 M USD |
| 2021 | 85.39 M USD | -70.79 M USD | -71.72 M USD |
| 2022 | 78.6 M USD | -94.54 M USD | -98.04 M USD |
| 2023e | 78.03 M USD | -91.21 M USD | -116.1 M USD |
| 2024e | 104.06 M USD | -53.08 M USD | -59.16 M USD |
| 2025e | 135.93 M USD | -44.17 M USD | -28.07 M USD |
| 2026e | 182.58 M USD | 0 USD | -27.26 M USD |
PhenomeX stock margins US0843101017 · A2P9RR
The PhenomeX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PhenomeX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PhenomeX.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the PhenomeX's sales revenue. A higher gross margin percentage indicates that the PhenomeX retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the PhenomeX's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the PhenomeX's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PhenomeX's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PhenomeX. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PhenomeX's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
PhenomeX Margin History
| PhenomeX Gross margin | PhenomeX Profit margin | PhenomeX EBIT margin | PhenomeX Profit margin |
|---|---|---|---|
| 2026e | 68.42 % | 0 % | -14.93 % |
| 2025e | 68.42 % | -32.49 % | -20.65 % |
| 2024e | 68.42 % | -51.01 % | -56.85 % |
| 2023e | 68.42 % | -116.9 % | -148.8 % |
| 2022 | 68.42 % | -120.28 % | -124.73 % |
| 2021 | 66.23 % | -82.9 % | -83.99 % |
| 2020 | 69.3 % | -62.81 % | -67.37 % |
| 2019 | 76.7 % | -29.18 % | -37.93 % |
| 2018 | 73.87 % | -67.6 % | -84.79 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 73.87 % | -67.6 % | -84.79 % |
| 2019 | 76.7 % | -29.18 % | -37.93 % |
| 2020 | 69.3 % | -62.81 % | -67.37 % |
| 2021 | 66.23 % | -82.9 % | -83.99 % |
| 2022 | 68.42 % | -120.28 % | -124.73 % |
| 2023e | 68.42 % | -116.9 % | -148.8 % |
| 2024e | 68.42 % | -51.01 % | -56.85 % |
| 2025e | 68.42 % | -32.49 % | -20.65 % |
| 2026e | 68.42 % | 0 % | -14.93 % |
PhenomeX Aktienanalyse
What does PhenomeX do?
The company Berkeley Lights Inc. (BLI) is a biotech startup that was founded in 2011 by Eric Hobbs and Igor Khandros in California. They both had experience in the semiconductor electronics field and decided to utilize their skills to develop a new technology that allows researchers to quickly and efficiently investigate cell-specific processes. The concept behind BLI is based on a novel technology called the "Beacon system." Cells are held on thousands of tiny microchips and can be selectively manipulated using beams of light. The Beacon system enables researchers to isolate, analyze, and select cells rapidly and efficiently, significantly speeding up and simplifying the research process. BLI's business model can be described as B2B, as the company sells its technology and services to other companies in the biotech industry. BLI has two different divisions in which it utilizes its technology and expertise: the "OptoSelect" program and the "Beacon Discovery" program. BLI's OptoSelect program offers customers the ability to select precise and specific cell lines from a large array of cultures. BLI utilizes its Beacon technology to quickly and efficiently isolate and select cells, saving valuable time and resources for researchers. These cell lines can then be used in the development of drugs and therapies, increasing the chances of successful market introduction. BLI's Beacon Discovery program is focused on accelerating the discovery process of new drugs and therapies. BLI works closely with its customers to expedite the drug development process. By using the Beacon technology, it is possible to identify and test potential drug candidates more quickly, significantly reducing the development time. BLI also offers a range of products based on the Beacon technology. These include devices such as the Lightning™ Digital Array, a system for multi-omics analysis of gene expression, immune response, and cell cycle; the Beacon® Controller, a system for controlling the Beacon® microchip platform; and the Beacon® Pak for consumables. Since its founding, BLI has conducted multiple funding rounds and raised over $180 million for the development of its technology and services. The company has established strong partnerships with leading companies in the biotech industry and collaborates closely with researchers and universities to advance its technology. Overall, BLI has established itself as a leading provider of biotech technologies. Through the use of its Beacon technology, the company has accelerated and simplified the process of cell analysis and selection, speeding up the development of new drugs and therapies and increasing the chances of successful market introduction. With its state-of-the-art products and services, BLI is well-positioned to continue playing a significant role in the biotech industry in the future. PhenomeX ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing PhenomeX's EBIT
PhenomeX's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of PhenomeX's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
PhenomeX's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in PhenomeX’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about PhenomeX Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company PhenomeX.
How has the EBIT of PhenomeX developed in recent years?
The EBIT of PhenomeX has increased by -41.808% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company PhenomeX?
The EBIT of PhenomeX is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does PhenomeX pay?
Over the past 12 months, PhenomeX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PhenomeX is expected to pay a dividend of 0 USD.
What is the dividend yield of PhenomeX?
The current dividend yield of PhenomeX is .
When does PhenomeX pay dividends?
PhenomeX pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of PhenomeX?
PhenomeX paid dividends every year for the past 0 years.
What is the dividend of PhenomeX?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is PhenomeX located?
PhenomeX is assigned to the 'Health' sector.
Wann musste ich die Aktien von PhenomeX kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of PhenomeX from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.
When did PhenomeX pay the last dividend?
The last dividend was paid out on 7/1/2024.
What was the dividend of PhenomeX in the year 2023?
In the year 2023, PhenomeX distributed 0 USD as dividends.
In which currency does PhenomeX pay out the dividend?
The dividends of PhenomeX are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von PhenomeX
Our stock analysis for PhenomeX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PhenomeX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.